Market

Hypertension (high blood pressure) is a worldwide epidemic. The American Heart Association (www.americanheart.org) estimates that in the U.S. alone nearly one in three adults has hypertension with a majority having major a co-morbidity of obesity. Global prevalence of each hypertension, obesity and ORH is increasing rapidly.  It is estimated that by 2025 more than 1.5 billion people will suffer from hypertension worldwide. Modern lifestyles, such as poor diet, lack of exercise and resulting obesity, are the key drivers of growth in global hypertension markets, especially in North America and Europe. The global market for antihypertensives is one of the pharmaceutical industry’s largest and most profitable markets. With increasing prevalence of hypertension and ORH, HTI expects the market potential for HTI-101 as a new combination therapy for refractory ORH to be robust.